Skip Navigation
Skip to contents

Cancer Res Treat : Cancer Research and Treatment

OPEN ACCESS

Search

Page Path
HOME > Search
7 "Dae Sik Kim"
Filter
Filter
Article category
Keywords
Publication year
Authors
Original Articles
Hematologic malignancy
Long-term Psychiatric and Endocrine Complications Following Hematopoietic Stem Cell Transplantation in Hematologic Disease in Korea: A Nation-Wide Cohort Study
Min Ji Jeon, Eunjin Noh, Seok Joo Moon, Eun Sang Yu, Chul Won Choi, Dae Sik Kim, Eun Joo Kang
Cancer Res Treat. 2024;56(4):1262-1269.   Published online May 9, 2024
DOI: https://doi.org/10.4143/crt.2024.047
AbstractAbstract PDFPubReaderePub
Purpose
Numerous patients experience long-term complications after hematopoietic stem cell transplantation (HSCT). This study aimed to identify the frequency and risk factors for psychiatric and endocrine complications following HSCT through big data analyses.
Materials and Methods
We established a cohort of patients with hematologic disease who underwent HSCT in Korea between 2010 and 2012 using the Health Insurance Review & Assessment Service data. A total of 3,636 patients were identified, and insurance claims were tracked using psychiatric and endocrine diagnostic International Classification of Diseases, 10th Revision codes for the ensuing decade. We identified the incidence rates of long-term complications based on the baseline disease and HSCT type. Prognostic factors for each complication were scrutinized using logistic regression analysis.
Results
A total of 1,879 patients underwent allogeneic HSCT and 1,757 patients received autologous HSCT. Post-HSCT, 506 patients were diagnosed with depression, 465 with anxiety disorders, and 659 with diabetes. The highest incidence of long-term complications occurred within the first year post-HSCT (12.2%), subsequently decreasing over time. Risk factors for depressive disorders after allogeneic HSCT included female sex, a total body irradiation–based conditioning regimen, and cyclosporine. Identified risk factors for diabetes mellitus comprised old age, total body irradiation–based conditioning regimen, and non-antithymocyte globulin protocol. Regarding autologous HSCT, only female sex was identified as a risk factor for depressive disorders, whereas elderly patients and those with multiple myeloma were identified as poor prognostic factors for diabetes mellitus.
Conclusion
The incidence of long-term psychiatric and endocrine complications post-HSCT remains high, and patients with risk factors for these complications require vigilant follow-up.
  • 1,756 View
  • 96 Download
Close layer
Association of Single Nucleotide Polymorphisms in PIM-1 Gene with the Risk of Korean Lung Cancer
Dae Sik Kim, Jae Sook Sung, Eun Soon Shin, Jeong-Seon Ryu, In Keun Choi, Kyong Hwa Park, Yong Park, Eui Bae Kim, Seh Jong Park, Yeul Hong Kim
Cancer Res Treat. 2008;40(4):190-196.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.190
AbstractAbstract PDFPubReaderePub
Purpose

The expression of the PIM-1 gene, which is a proto-oncogene that encodes a serine/threonine kinase, is associated with multiple cellular functions such as proliferation, differentiation, apoptosis and tumorigenesis. In particular, several studies have reported that the PIM-1 gene is associated with the development of lymphoma, leukemia and prostate cancer. Therefore, this study was conducted to evaluate the association between the single nucleotide polymorphisms in the PIM-1 gene and the risk of lung cancer occurrence in the Korean population.

Materials and Methods

To evaluate the role of the PIM-1 gene in the development of lung cancer, the genotypes of the PIM-1 gene were determined in 408 lung cancer patients and 410 normal subjects.

Results

We found that the T-C-T-C haplotypes of the PIM-1 gene (-1196 T>C, IVS4 +55 T>C, IVS4 +1416 T>A and +3684 C>A) were associated with an increased risk of lung cancer [adjusted odds ratio (aOR): 3.98; 95% CI: 1.24~12.75, p-value: 0.020]. In particular, these haplotypes showed an increased risk of lung cancer in males (aOR: 5.67; 95% CI: 1.32~24.30, p-value: 0.019) and smokers (aOR: 7.82; 95% CI: 1.75~34.98, p-value: 0.007).

Conclusions

The present results suggest that the T-C-T-C haplotype of the PIM-1 gene could influence the risk of developing smoking-related lung cancer in the Korean population. Additional functional studies with an larger sample sized analysis are warranted to reconfirm our findings.

Citations

Citations to this article as recorded by  
  • A review on structure-function mechanism and signaling pathway of serine/threonine protein PIM kinases as a therapeutic target
    Ajaya Kumar Rout, Budheswar Dehury, Satya Narayan Parida, Sushree Swati Rout, Rajkumar Jena, Neha Kaushik, Nagendra Kumar Kaushik, Sukanta Kumar Pradhan, Chita Ranjan Sahoo, Ashok Kumar Singh, Meenakshi Arya, Bijay Kumar Behera
    International Journal of Biological Macromolecules.2024; 270: 132030.     CrossRef
  • Impact of Pim1 mutations on the survival outcomes of patients with breast cancer: Insights from a clinical study
    Syed Sultan Beevi, Kavitha Anbrasu, Vinod Kumar Verma, Nagesh Kishan Panchal, Krishna Kiran Kannepalli, Raghu Ram Pillarisetti, Sailaja Madigubba, Jyotsana Dwivedi, Neha Damodar, Radhika Chowdary Darapuneni
    Human Gene.2024; 40: 201295.     CrossRef
  • HCG11 inhibits salivary adenoid cystic carcinoma by upregulating EphA2 via binding to miR-1297
    Shujuan Yan, Meng Wang
    Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology.2023; 135(2): 257.     CrossRef
  • Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
    Aanchal Rathi, Dhiraj Kumar, Gulam Mustafa Hasan, Mohammad Mahfuzul Haque, Md Imtaiyaz Hassan
    Biochimica et Biophysica Acta (BBA) - General Subjects.2021; 1865(11): 129995.     CrossRef
  • Loss of PIM1 correlates with progression and prognosis of salivary adenoid cystic carcinoma (SACC)
    Jiajie Xu, Xin Zhu, Qingling Li, Chao Chen, Zhenying Guo, Zhuo Tan, Chuanming Zheng, Minghua Ge
    Cancer Cell International.2018;[Epub]     CrossRef
  • PIM Kinase as an Executional Target in Cancer
    Xinning Zhang, Mengqiu Song, Joydeb Kumar Kundu, Mee-Hyun Lee, Zhen-Zhen Liu
    Journal of Cancer Prevention.2018; 23(3): 109.     CrossRef
  • HistoneH3 demethylase JMJD2A promotes growth of liver cancer cells through up-regulating miR372
    Jiahui An, Jie Xu, Jiao Li, Song Jia, Xiaonan Li, Yanan Lu, Yuxin Yang, Zhuojia Lin, Xiaoru Xin, Mengying Wu, Qidi Zheng, Hu Pu, Xin Gui, Tianming Li, Dongdong Lu
    Oncotarget.2017; 8(30): 49093.     CrossRef
  • Expressions of osteopontin (OPN), ανβ3 and Pim-1 associated with poor prognosis in non-small cell lung cancer (NSCLC)
    Yi Jin, Da-yue Tong, Lu-ying Tang, Jian-ning Chen, Jing Zhou, Zhi-ying Feng, Chun-kui Shao
    Chinese Journal of Cancer Research.2012; 24(2): 103.     CrossRef
  • Overexpression of Osteopontin, αvβ3 and Pim-1 Associated with Prognostically Important Clinicopathologic Variables in Non-Small Cell Lung Cancer
    Yi Jin, Da-yue Tong, Jian-ning Chen, Zhi-ying Feng, Jian-yong Yang, Chun-kui Shao, Jia-ping Li, Rossella Rota
    PLoS ONE.2012; 7(10): e48575.     CrossRef
  • No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population
    Jae-Sook Sung, Kyong-Hwa Park, Seung-Tae Kim, Jae-Hong Seo, Sang-Won Shin, Jun-Suk Kim, Yeul-Hong Kim
    Genomics & Informatics.2010; 8(4): 194.     CrossRef
  • 11,698 View
  • 85 Download
  • 10 Crossref
Close layer
Clinical Factors Related to Suspected Second Primary Lung Cancer Development in Patients with Head and Neck Cancer
Eui Bae Kim, Yong Park, Seh Jong Park, Dae Sik Kim, Jee Won Kim, Hee Yun Seo, Hwa Jung Sung, In Keun Choi, Kyong Hwa Park, Sang Cheul Oh, Chul Won Choi, Byung Soo Kim, Yeul Hong Kim, Jun Suk Kim, Sang Won Shin, Chul Yong Kim, Kwang-Yoon Jung
Cancer Res Treat. 2008;40(4):178-183.   Published online December 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.4.178
AbstractAbstract PDFPubReaderePub
Purpose

The rate of second primary lung cancer development for patients with head and neck cancer (HNC) has been noted. The aim of our study was to evaluate the incidence and clinical features of suspected second primary lung cancer that developed in patients with primary HNC.

Materials and Methods

We conducted a retrospective study of 469 patients who were newly diagnosed with HNC at the Korea University Medical Center between January 2000 and December 2006.

Results

A total of 469 patients were included (389 men and 80 women). Eighteen patients (3.8%) had suspected second primary lung cancers. Statistically significant clinical variables for lung cancer development included the origin site for the primary HNC (oro-hypopharynx and larynx) (p=0.048), abnormal chest x-ray findings (p=0.027) and the histological HNC type (squamous cell carcinoma) (p=0.032). When the second primary lung cancers were combined with HNCs, the adjusted overall survival of patients with a second primary lung cancer was 16 months (p<0.001).

Conclusions

Considering the relative risk factors for a second primary lung cancer developing in patients with HNC, advanced diagnostic tools, such as chest CT or PET CT scan, should be applied for the early detection of a second primary lung cancer.

Citations

Citations to this article as recorded by  
  • Long-Term Survival in Metachronous Primary Malignancies: Stage III Nasopharyngeal Cancer and Stage IV Non-Small-Cell Lung Cancer
    Gabriela Rahnea-Nita, Alexandru Nechifor, Mihai-Teodor Georgescu, Dorel Firescu, Adrian-Cornel Maier, Radu-Valeriu Toma, Valentin Titus Grigorean, Liliana-Florina Andronache, Roxana-Andreea Rahnea-Nita, Ionut Simion Coman, Laura-Florentina Rebegea
    Journal of Clinical Medicine.2025; 14(10): 3299.     CrossRef
  • African American race as a risk factor associated with a second primary lung cancer after initial primary head and neck cancer
    Yusra F. Shao, Seongho Kim, John D. Cramer, Dina Farhat, Jeffrey Hotaling, Syed Naweed Raza, George Yoo, Ho‐sheng Lin, Harold Kim, Ammar Sukari, Misako Nagasaka
    Head & Neck.2022; 44(10): 2069.     CrossRef
  • Should fluorodeoxyglucose positron emission tomography/computed tomography be the first-line imaging investigation for restaging the laryngeal carcinoma patients?
    Tarun Jain, Guman Singh, Sumit Goyal, Ajay Yadav, Dinesh Yadav, Nitin Khunteta, Hemant Malhotra
    World Journal of Nuclear Medicine.2021; 20(02): 164.     CrossRef
  • Modern Radiology in the Management of Head and Neck Cancer
    G.J.C. Burkill, R.M. Evans, V.V. Raman, S.E.J. Connor
    Clinical Oncology.2016; 28(7): 440.     CrossRef
  • Synchronous Squamous Cell Carcinoma and Chronic Lymphocytic Leukemia of the Palate
    Pablo Rosado, Soledad Fernández, Luis Junquera, Juan Carlos De Vicente
    Journal of Craniofacial Surgery.2011; 22(1): 348.     CrossRef
  • 11,495 View
  • 72 Download
  • 5 Crossref
Close layer
The Bone Morphogenesis Protein-2 (BMP-2) is Associated with Progression to Metastatic Disease in Gastric Cancer
Yong Park, Jee Won Kim, Dae Sik Kim, Eui Bae Kim, Se Jong Park, Jin Yong Park, Woo Suk Choi, Jong Gyu Song, Hee Yun Seo, Sang Cheul Oh, Byung Soo Kim, Jong Jae Park, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2008;40(3):127-132.   Published online September 30, 2008
DOI: https://doi.org/10.4143/crt.2008.40.3.127
AbstractAbstract PDFPubReaderePub
Purpose

Bone Morphogenetic Proteins (BMPs) are members of the TGF-β superfamily and it has been demonstrated that BMPs enhance migration, invasion and metastasis. The purpose of this study was to identify the association between the serum BMP-2 level and the progression status of gastric cancer.

Materials and Methods

Fifty-five patients with metastatic gastric cancer (metastatic disease group), six patients with early gastric cancer without lymph node metastasis (the EGC group), and ten healthy control subjects were enrolled in this study. The serum BMP-2 level was quantified by use of a commercially available ELISA kit. In EGC group patients and patients with metastatic disease, whole blood was obtained before endoscopic mucosal resection and before the commencement of a scheduled cycle of systemic chemotherapy, respectively.

Results

No significant difference in the mean serum BMP-2 levels was observed between the control subjects and the EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p=1.0). However, the metastatic disease group patients had a significantly higher level of serum BMP (179.61 pg/ml) than the control subjects and EGC group patients (87.95 pg/ml for the control subjects and 84.50 pg/ml for the EGC group, p<0.0001). Moreover, the mean serum BMP-2 level from patients with a bone metastasis was significantly higher than the mean serum BMP-2 level from patients without a bone metastasis (204.73 pg/ml versus 173.33 pg/ml, p=0.021).

Conclusions

BMP-2 seems to have a role in progression to metastatic disease in gastric cancer, especially in the late stage of tumorigenesis, including invasion and metastasis. BMP-2 may facilitate bone metastasis in gastric cancer. To confirm these findings, further studies are required with tissue specimens and the use of a cancer cell line.

Citations

Citations to this article as recorded by  
  • Novel Biomarkers in Evaluating Cardiac Function in Patients on Hemodialysis—A Pilot Prospective Observational Cohort Study
    Lazar Chisavu, Viviana Mihaela Ivan, Adelina Mihaescu, Flavia Chisavu, Oana Schiller, Luciana Marc, Flaviu Bob, Adalbert Schiller
    Diagnostics.2024; 14(6): 664.     CrossRef
  • Duality of bone morphogenetic proteins in cancer: A comprehensive analysis
    Tanu Sharma, Anmol Kapoor, Chandi C. Mandal
    Journal of Cellular Physiology.2022; 237(8): 3127.     CrossRef
  • BMP2 inhibits cell proliferation by downregulating EZH2 in gastric cancer
    Zilu Chen, Liyue Yuan, Xiaopeng Li, Junhui Yu, Zhengshui Xu
    Cell Cycle.2022; 21(21): 2298.     CrossRef
  • Emerging Roles for Browning of White Adipose Tissue in Prostate Cancer Malignant Behaviour
    Alejandro Álvarez-Artime, Belén García-Soler, Rosa María Sainz, Juan Carlos Mayo
    International Journal of Molecular Sciences.2021; 22(11): 5560.     CrossRef
  • Magnesium ions regulate mesenchymal stem cells population and osteogenic differentiation: A fuzzy agent-based modeling approach
    Jalil Nourisa, Berit Zeller-Plumhoff, Heike Helmholz, Bérengère Luthringer-Feyerabend, Vladimir Ivannikov, Regine Willumeit-Römer
    Computational and Structural Biotechnology Journal.2021; 19: 4110.     CrossRef
  • BMP Signaling in Development, Stem Cells, and Diseases of the Gastrointestinal Tract
    Yongchun Zhang, Jianwen Que
    Annual Review of Physiology.2020; 82(1): 251.     CrossRef
  • Relaxin enhances bone regeneration with BMP‐2‐loaded hydroxyapatite microspheres
    Sahitya Injamuri, Mohamed N. Rahaman, Youqu Shen, Yue‐Wern Huang
    Journal of Biomedical Materials Research Part A.2020; 108(5): 1231.     CrossRef
  • Annatto-Derived Tocotrienol Promotes Mineralization of MC3T3-E1 Cells by Enhancing BMP-2 Protein Expression via Inhibiting RhoA Activation and HMG-CoA Reductase Gene Expression


    Wan Nuraini Wan Hasan, Kok-Yong Chin, Norzana Abd Ghafar, Ima Nirwana Soelaiman
    Drug Design, Development and Therapy.2020; Volume 14: 969.     CrossRef
  • Detection of circulating BMP5 as a risk factor for Barrett’s esophagus
    Ana C. P. Correia, Silvia Calpe, Nahid Mostafavi, Sanne Johanna Maria Hoefnagel, Maria del Carmen Sancho-Serra, Patricia S. de Koning, Kausilia K. Krishnadath
    Scientific Reports.2020;[Epub]     CrossRef
  • The Dual Role of Bone Morphogenetic Proteins in Cancer
    Duc-Hiep Bach, Hyen Joo Park, Sang Kook Lee
    Molecular Therapy - Oncolytics.2018; 8: 1.     CrossRef
  • Embryonic bone morphogenetic protein and nodal induce invasion in melanocytes and melanoma cells
    Tobias Sinnberg, Heike Niessner, Mitch P. Levesque, Christoph Dettweiler, Claus Garbe, Christian Busch
    Biology Open.2018;[Epub]     CrossRef
  • Decreased expression of bone morphogenetic protein-2 is correlated with biochemical recurrence in prostate cancer: Immunohistochemical analysis
    Bum Sik Tae, Seok Cho, Hyun Cheol Kim, Cheol Hwan Kim, Seok Ho Kang, Jeong Gu Lee, Je Jong Kim, Hong Seok Park, Jun Cheon, Mi Mi Oh, Sung Gu Kang
    Scientific Reports.2018;[Epub]     CrossRef
  • Computational model of mesenchymal migration in 3D under chemotaxis
    F. O. Ribeiro, M. J. Gómez-Benito, J. Folgado, P. R. Fernandes, J. M. García-Aznar
    Computer Methods in Biomechanics and Biomedical Engineering.2017; 20(1): 59.     CrossRef
  • Bone morphogenetic protein-2 and tumor growth: Diverse effects and possibilities for therapy
    Haijun Tian, Jie Zhao, Elsa J. Brochmann, Jeffrey C. Wang, Samuel S. Murray
    Cytokine & Growth Factor Reviews.2017; 34: 73.     CrossRef
  • BMP signaling pathways affect differently migration and invasion of esophageal squamous cancer cells
    Min Hu, Facai Cui, Fengzhen Liu, Jinlin Wang, Xiaoxia Wei, Yi Li
    International Journal of Oncology.2017; 50(1): 193.     CrossRef
  • Overexpression of colorectal cancer oncogene CHRDL2 predicts a poor prognosis
    Jian Sun, Xuan Liu, Hong Gao, Long Zhang, Qing Ji, Ziyuan Wang, Lihong Zhou, Yan Wang, Hua Sui, Zhongze Fan, Qi Li
    Oncotarget.2017; 8(7): 11489.     CrossRef
  • BMP10 inhibited the growth and migration of gastric cancer cells
    Haiming Lei, Jian Wang, Peihua Lu, Xinghua Si, Koulan Han, Tingyan Ruan, Junjie Lu
    Tumor Biology.2016; 37(3): 3025.     CrossRef
  • How does the pathophysiological context influence delivery of bone growth factors?
    Xiaohua Yu, Darilis Suárez-González, Andrew S. Khalil, William L. Murphy
    Advanced Drug Delivery Reviews.2015; 84: 68.     CrossRef
  • Inactivation of the Phosphatidylinositol 3‐Kinase/Akt Pathway is Involved in BMP9‐mediated Tumor‐suppressive Effects in Gastric Cancer Cells
    Liang Duan, Liwei Ye, Rui Wu, Haiyan Wang, Xueru Li, Huan Li, Shimei Yuan, He Zha, Hui Sun, Yunyuan Zhang, Xian Chen, Yan Zhang, Lan Zhou
    Journal of Cellular Biochemistry.2015; 116(6): 1080.     CrossRef
  • Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2
    Yun-Jung Choi, Patrick N. Ingram, Kun Yang, Lan Coffman, Mangala Iyengar, Shoumei Bai, Dafydd G. Thomas, Euisik Yoon, Ronald J. Buckanovich
    Proceedings of the National Academy of Sciences.2015;[Epub]     CrossRef
  • Association Between BMP-2 and Carcinogenicity
    Branko Skovrlj, Steven M. Koehler, Paul A. Anderson, Sheeraz A. Qureshi, Andrew C. Hecht, James C. Iatridis, Samuel K. Cho
    SPINE.2015; 40(23): 1862.     CrossRef
  • In silico Mechano-Chemical Model of Bone Healing for the Regeneration of Critical Defects: The Effect of BMP-2
    Frederico O. Ribeiro, María José Gómez-Benito, João Folgado, Paulo R. Fernandes, José Manuel García-Aznar, Masaya Yamamoto
    PLOS ONE.2015; 10(6): e0127722.     CrossRef
  • Comparative transcriptome analysis between metastatic and non-metastatic gastric cancer reveals potential biomarkers
    DAN FENG, XIAOFEI YE, ZHENXIN ZHU, ZIRAN WEI, QINGPING CAI, YAJIE WANG
    Molecular Medicine Reports.2015; 11(1): 386.     CrossRef
  • Gastric stem cells and gastric cancer stem cells
    Myoung-Eun Han, Sae-Ock Oh
    Anatomy & Cell Biology.2013; 46(1): 8.     CrossRef
  • Cancer stem cells: the ‘heartbeat’ of gastric cancer
    Guihua Xu, Jie Shen, Xiaohui Ou Yang, Masakiyo Sasahara, Xiulan Su
    Journal of Gastroenterology.2013; 48(7): 781.     CrossRef
  • Serum BMP-2 Up-regulation as an Indicator of Poor Survival in Advanced Non-small Cell Lung Cancer Patients
    Zheng-Hua Fei, Cheng-Yun Yao, Xiao-Lei Yang, Xin-En Huang, Sheng-Lin Ma
    Asian Pacific Journal of Cancer Prevention.2013; 14(9): 5293.     CrossRef
  • P‐glycoprotein (ABCB1) inhibited network of mitochondrion transport along microtubule and BMP signal‐induced cell shape in chimpanzee left cerebrum by systems‐theoretical analysis
    Hong Lin, Lin Wang, Minghu Jiang, Juxiang Huang, Lianxiu Qi
    Cell Biochemistry and Function.2012; 30(7): 582.     CrossRef
  • Bone–vasculature interactions in the mandible: Is bone an angiogenic tissue?
    E.M. Dietrich, K. Antoniades
    Medical Hypotheses.2012; 79(5): 582.     CrossRef
  • Major Determinants of BMP-2 Serum Levels in Hemodialysis Patients
    Elísio Costa, Joana Coimbra, Cristina Catarino, Sandra Ribeiro, Flávio Reis, Henrique Nascimento, João Fernandes, Vasco Miranda, Maria do Sameiro Faria, Luís Belo, Alice Santos-Silva
    Renal Failure.2012; 34(10): 1355.     CrossRef
  • Bone Morphogenetic Protein-4-induced Epithelial-Mesenchymal Transition and Invasiveness Through Smad1-mediated Signal Pathway in Squamous Cell Carcinoma of the Head and Neck
    Ting Xu, Chang-yun Yu, Jin-jie Sun, Yong Liu, Xing-wei Wang, Lei-ming Pi, Yong-quan Tian, Xin Zhang
    Archives of Medical Research.2011; 42(2): 128.     CrossRef
  • Bone Morphogenetic Protein-2 and -4 Play Tumor Suppressive Roles in Human Diffuse-Type Gastric Carcinoma
    Yo-taro Shirai, Shogo Ehata, Masakazu Yashiro, Kazuyoshi Yanagihara, Kosei Hirakawa, Kohei Miyazono
    The American Journal of Pathology.2011; 179(6): 2920.     CrossRef
  • Metastatic function of BMP-2 in gastric cancer cells: The role of PI3K/AKT, MAPK, the NF-κB pathway, and MMP-9 expression
    Myoung Hee Kang, Sang Cheul Oh, Hyun Joo Lee, Han Na Kang, Jung Lim Kim, Jun Suk Kim, Young A. Yoo
    Experimental Cell Research.2011; 317(12): 1746.     CrossRef
  • Downregulation of hemojuvelin prevents inhibitory effects of bone morphogenetic proteins on iron metabolism in hepatocellular carcinoma
    Ulrike Maegdefrau, Stephanie Arndt, Georgi Kivorski, Claus Hellerbrand, Anja-Katrin Bosserhoff
    Laboratory Investigation.2011; 91(11): 1615.     CrossRef
  • Coding polymorphisms of bone morphogenetic protein 2 contribute to the development of childhood IgA nephropathy
    JIN-SOON SUH, WON-HO HAHN, JONG SEOK LEE, HAE JEONG PARK, MI-JA KIM, SUNG WOOK KANG, JOO-HO CHUNG, BYOUNG-SOO CHO
    Experimental and Therapeutic Medicine.2011; 2(2): 337.     CrossRef
  • Bone morphogenetic protein-2 levels are elevated in the patients with gastric cancer and correlate with disease progression
    Yong Park, Myoung Hee Kang, Hee Yeon Seo, Joong Min Park, Chul Won Choi, Yeul Hong Kim, In Sun Kim, Jun Suk Kim, Sang Cheul Oh
    Medical Oncology.2010; 27(4): 1192.     CrossRef
  • The Yin and Yang of bone morphogenetic proteins in cancer
    Ashok Singh, Rebecca J. Morris
    Cytokine & Growth Factor Reviews.2010; 21(4): 299.     CrossRef
  • BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway
    Myoung Hee Kang, Jun Suk Kim, Ji Eun Seo, Sang Cheul Oh, Young A. Yoo
    Experimental Cell Research.2010; 316(1): 24.     CrossRef
  • 12,490 View
  • 76 Download
  • 37 Crossref
Close layer
Case Report
Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy
Eui Bae Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Kyoung Ho Rho, Seok Jin Kim
Cancer Res Treat. 2008;40(1):36-38.   Published online March 31, 2008
DOI: https://doi.org/10.4143/crt.2008.40.1.36
AbstractAbstract PDFPubReaderePub

Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows: HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.

Citations

Citations to this article as recorded by  
  • Recurrence and influencing factors of hepatitis B surface antigen seroclearance induced by peginterferon alpha-based regimens
    Rui Lu, Meng Zhang, Zi-Han Liu, Miao Hao, Yan Tian, Mei Li, Feng-Ping Wu, Wen-Jun Wang, Juan-Juan Shi, Xin Zhang, Xiao-Li Jia, Zi-Cheng Jiang, Xue-Mei Li, Guang-Hua Xu, Ya-Ping Li, Shuang-Suo Dang
    World Journal of Gastroenterology.2024; 30(44): 4725.     CrossRef
  • Very late-onset hepatitis B reactivation following chemoimmunotherapy
    Edward R. Scheffer Cliff, Joe Sasadeusz, Kumar Visvanathan, Andrew Grigg
    Leukemia & Lymphoma.2022; 63(4): 991.     CrossRef
  • Development and validation of a nomogram for steroid-resistance prediction in immune thrombocytopenia patients
    Jieni Yu, Zhiqiang Xu, Yuanyuan Zhuo, Huahua Wei, Yinhai Ye, Qinhong Xu, Youli Li, Lihong Yu, Weiying Feng, Pan Hong, Kejie Zhang
    Hematology.2021; 26(1): 956.     CrossRef
  • Hepatitis B virus reactivation with corticosteroid therapy in patients with adrenal insufficiency
    Masako Hatano, Toshihide Mimura, Akira Shimada, Mitsuhiko Noda, Shigehiro Katayama
    Endocrinology, Diabetes & Metabolism.2019;[Epub]     CrossRef
  • Late reactivation of occult hepatitis B virus infection in a patient with chronic lymphocytic leukemia after rituximab and fludarabine-based regimen
    Nuria Dominguez, Maria Luisa Manzano, Raquel Muñoz, Ana Martin, Inmaculada Fernandez, Gregorio Castellano
    Leukemia & Lymphoma.2015; 56(4): 1160.     CrossRef
  • Giving rituximab in patients with occult or resolved hepatitis B virus infection: are the current guidelines good enough?
    Jesse Civan, Hie Won Hann
    Expert Opinion on Drug Safety.2015; 14(6): 865.     CrossRef
  • Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy
    Mauro Viganò, Giampaolo Mangia, Pietro Lampertico
    Expert Opinion on Biological Therapy.2014; 14(7): 1019.     CrossRef
  • A Case of Reactivation of Hepatitis B and Fulminant Hepatitis which developed 3 months following Chemotherapy Including Rituximab in a Patient with Lymphoma
    Tae Won Lim, Hee Taek Oh, Seung Un Song, Hae Won Lee, Ji Yeon Kim, Seon Ja Park
    Kosin Medical Journal.2014; 29(2): 161.     CrossRef
  • Occult Hepatitis B Virus Infection: Transmission and Reactivation
    Sang Hee Song, Seong Gyu Hwang
    The Korean Journal of Gastroenterology.2013; 62(3): 148.     CrossRef
  • Reactivation of Hepatitis B Virus Following Systemic Chemotherapy for Malignant Lymphoma
    Seung Jun Jang, Young Kul Jung, Hae Lim Baek, Hyun Hwa Yoon, Seung Kak Shin, Jun Shik Hong, Jin Ny Park, Oh Sang Kwon, Yun Soo Kim, Duck Joo Choi, Jae Hoon Lee, Ju Hyun Kim
    Korean Journal of Medicine.2013; 85(6): 598.     CrossRef
  • Occult Hepatitis B: Clinical Viewpoint and Management
    Mehdi Zobeiri
    Hepatitis Research and Treatment.2013; 2013: 1.     CrossRef
  • Highly Sensitive Detection of Hepatitis B Virus Surface Antigen by Use of a Semiautomated Immune Complex Transfer Chemiluminescence Enzyme Immunoassay
    Kazuhiko Takeda, Mari Maruki, Takahiro Yamagaito, Machiko Muramatsu, Yasuhiro Sakai, Hiroaki Tobimatsu, Hironori Kobayashi, Yoshiteru Mizuno, Yukio Hamaguchi
    Journal of Clinical Microbiology.2013; 51(7): 2238.     CrossRef
  • Reactivation of hepatitis B virus following rituximab-plus-steroid combination chemotherapy
    Shigeru Kusumoto, Yasuhito Tanaka, Ryuzo Ueda, Masashi Mizokami
    Journal of Gastroenterology.2011; 46(1): 9.     CrossRef
  • Fulminant Hepatic Failure with Hepatitis B Virus Reactivation after Rituximab Treatment in a Patient with Resolved Hepatitis B
    Seong Min Chung, Joo Hyun Sohn, Tae Yeob Kim, Ki Deok Yoo, Yong Woo Ahn, Joong Ho Bae, Yong Cheol Jeon, Jung Hye Choi
    The Korean Journal of Gastroenterology.2010; 55(4): 266.     CrossRef
  • Exacerbation of chronic idiopathic thrombocytopenic purpura following reactivation of an occult hepatitis B
    Alessandro Allegra, Giuseppa Penna, Andrea Alonci, Angela Granata, Arianna D’Angelo, Caterina Musolino
    Medical Oncology.2010; 27(3): 912.     CrossRef
  • 14,747 View
  • 91 Download
  • 15 Crossref
Close layer
Original Articles
Glucose Transporter-1 Expression in Squamous Cell Carcinoma of the Tongue
Yoon Seok Choi, Seok Jin Kim, Dae Sik Kim, Seh Jong Park, Yong Park, Hye Jin Shin, Kwang-Yoon Jung, Seung-Kuk Baek, Bong Kyung Shin, Jung Woo Choi, Byung Soo Kim, Sang Won Shin, Yeul Hong Kim, Jun Suk Kim
Cancer Res Treat. 2007;39(3):109-115.   Published online September 30, 2007
DOI: https://doi.org/10.4143/crt.2007.39.3.109
AbstractAbstract PDFPubReaderePub
Purpose

Tumor cells are known to express hypoxia-related proteins such as glucose transporter-1 (Glut-1). These hypoxia-induced changes may allow tumor cells to survive under sustained hypoxic microenvironments, and the surviving tumor cell under hypoxia may develop a more aggressive phenotype and so result in a poor prognosis.

Materials and Methods

The Glut-1 expression was analyzed by immunohistochemistry, and its association with the prognosis was assessed in 60 patients with squamous cell carcinoma of the tongue.

Results

The Glut-1 expression was diffuse with a membranous pattern, and the median percentage of Glut-1 positive tumor cells was 60% (range: 0.0~90.0%). A high Glut-1 expression (the percentage of positive tumor cells ≥ the median value, 60%) was associated with the location of primary lesion, lymph node metastasis status and disease stage (p<0.05). The expression of Glut-1 was correlated with the Ki-67 expression (r=0.406, p=0.001). Microvessel density, as represented by CD31 staining, was also correlated with the Glut-1 expression although its significance is weak (r=0.267, p=0.039). On the univariate analysis, the group with a high Glut-1 expression showed poorer overall survival than the group with a low Glut-1 expression (p<0.05). However, the Glut-1 expression failed to show any independent prognostic significance on the multivariate analysis.

Conclusion

The expression of Glut-1 may be useful for predicting the prognosis and determining the treatment strategy for the management of squamous cell carcinoma of the tongue.

Citations

Citations to this article as recorded by  
  • Study of expression of GLUT-1 in oral potentially malignant disorders and oral squamous cell carcinoma: An immuno-histochemical analysis
    Shylaja K. Attur, Anil Patel, Kailash M. Attur
    Journal of Oral and Maxillofacial Pathology.2024; 28(1): 70.     CrossRef
  • Prognostic value of glycolysis markers in head and neck squamous cell carcinoma: a meta-analysis
    Yanting Wang, Yuanyuan Li, Laibo Jiang, Xianyue Ren, Bin Cheng, Juan Xia
    Aging.2021; 13(5): 7284.     CrossRef
  • The Role of Glucose Transporters in Oral Squamous Cell Carcinoma
    Heinrich Botha, Camile S. Farah, Kendrick Koo, Nicola Cirillo, Michael McCullough, Rita Paolini, Antonio Celentano
    Biomolecules.2021; 11(8): 1070.     CrossRef
  • Glut 1 in Cancer Cells and the Inhibitory Action of Resveratrol as A Potential Therapeutic Strategy
    Angara Zambrano, Matías Molt, Elena Uribe, Mónica Salas
    International Journal of Molecular Sciences.2019; 20(13): 3374.     CrossRef
  • Can increased metabolic status be a grading tool for oral squamous cell carcinoma? A glucose transporter 1 immunoexpression study
    Abikshyeet Panda, Alokenath Bandyopadhyay, Gouse Mohiddin, Malvika Raghuvanshi, SanjayKumar Sahoo, Lipsa Bhuyan
    Nigerian Journal of Surgery.2019; 25(2): 203.     CrossRef
  • Plumbagin‐mediating GLUT1 suppresses the growth of human tongue squamous cell carcinoma
    S Na, J Zhang, X Zhou, A Tang, D Huang, Q Xu, D Xue, J Qiu
    Oral Diseases.2018; 24(6): 920.     CrossRef
  • Expression of GLUT-1 in oral squamous cell carcinoma in tobacco and non-tobacco users
    Neha Azad, Malti Kumari Maurya, Meenakshi Kar, Madhu Mati Goel, Ajay Kumar Singh, Mala Sagar, Divya Mehrotra, Vijay Kumar
    Journal of Oral Biology and Craniofacial Research.2016; 6(1): 25.     CrossRef
  • Distribution of Hypoxia-Inducible Factor-1α and Glucose Transporter-1 in Human Tongue Cancers
    Marcelo Gadelha Vasconcelos, Rodrigo Gadelha Vasconcelos, Denise Hélen Imaculada Pereira de Oliveira, Edilmar de Moura Santos, Leão Pereira Pinto, Éricka Janine Dantas da Silveira, Lélia Maria Guedes Queiroz
    Journal of Oral and Maxillofacial Surgery.2015; 73(9): 1753.     CrossRef
  • Expression of glucose transporters in cancers
    Leszek Szablewski
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer.2013; 1835(2): 164.     CrossRef
  • T-Type Ca2+Channels in Normal and Abnormal Brain Functions
    Eunji Cheong, Hee-Sup Shin
    Physiological Reviews.2013; 93(3): 961.     CrossRef
  • Glucose uptake mediated by glucose transporter 1 is essential for early tooth morphogenesis and size determination of murine molars
    Hiroko Ida-Yonemochi, Mitsushiro Nakatomi, Hidemitsu Harada, Hiroki Takata, Otto Baba, Hayato Ohshima
    Developmental Biology.2012; 363(1): 52.     CrossRef
  • Hypoxia-related protein expression and its clinicopathologic implication in carcinoma of unknown primary
    Ja Seung Koo, Haeryoung Kim
    Tumor Biology.2011; 32(5): 893.     CrossRef
  • 10,899 View
  • 57 Download
  • 12 Crossref
Close layer
Telomerase Activity in Invasive Breast Cancer
Deok Hwan Kim, Dae Sik Kim, Myung Soon Kim, Jung Ho Han, Yeon Rim Seo, Young Hye Ko, Chul Keun Park, Jung Hyun Yang, Hoe Jung Lee, Jong Sang Choi
J Korean Cancer Assoc. 1998;30(4):692-700.
AbstractAbstract PDF
No abstract available.
  • 2,817 View
  • 13 Download
Close layer

Cancer Res Treat : Cancer Research and Treatment
Close layer
TOP